Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry

Neuroscience

Volumn 98, Issue 4, 2000, Pages 759-770

  Singewald, N ^a,b   Sharp, T ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anxiety; Brainstem; c fos; Neuronal mapping; Panic disorder; Periaqueductal gray

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CAFFEINE; CHOLECYSTOKININ DERIVATIVE; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; YOHIMBINE;

ANXIETY; ARTICLE; BRAIN STEM; GENE EXPRESSION; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LOCUS CERULEUS; MICROPHOTOGRAPHY; NEUROANATOMY; ONCOGENE C FOS; PANIC; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RHOMBENCEPHALON;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANXIETY; CAFFEINE; CARBOLINES; CENTRAL NERVOUS SYSTEM STIMULANTS; GABA ANTAGONISTS; GENES, FOS; IMMUNOHISTOCHEMISTRY; MALE; PANIC; RATS; RHOMBENCEPHALON; YOHIMBINE;

EID: 0034124204     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00177-9     Document Type: Article

References (58)

1. Baldwin H.A., Johnston A.L., File S.E. Antagonistic effects of caffeine and yohimbine in animal tests of anxiety. Eur. J. Pharmac. 159:1989;211-215.
2. Bandler R., Shipley M.T. Columnar organization in the midbrain periaqueductal gray: modules for emotional expression. Trends Neurosci. 17:1994;379-389.
3. Beck C.H.M., Fibiger H.C. Conditioned fear-induced changes in behavior and in the expression of the immediate early gene c-fos: with and without diazepam pretreatment. J. Neurosci. 15:1995;709-720.
4. Beckett S.R.G., Marshall P.W., Marsden C.A. Intra-periaqueductal grey administration of mCPP potentiates a chemically-induced defence response. Br. J. Pharmac. 107:1992;8P.
5. Bennet H.J., Semba K. Immunohistochemical localization of caffeine-induced c-Fos protein expression in the rat brain. J. comp. Neurol. 401:1998;89-108.
6. Bernard J.F., Bandler R. Parallel circuits for emotional coping behaviour: new pieces in the puzzle. J. comp. Neurol. 401:1998;429-436.
7. Bhattacharya S.K., Satyan K.S., Chakrabarti A. Anxiogenic action of caffeine: an experimental study in rats. J. Psychopharmac. 11:1997;219-224.
8. Bing G., Stone E.A., Zhang Y., Filer D. Immunohistochemical studies of noradrenergic-induced expression of c-fos in the rat CNS. Brain Res. 592:1992;57-62.
9. Blanchard R.J., Griebel G., Henrie J.A., Blanchard D.C. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci. Biobehav. Rev. 21:1997;783-789.
10. Bourin M., Baker G.B., Bradwejn J. Neurobiology of panic disorders. J. psychosomat. Res. 44:1998;163-180.
11. Bradwejn J., Koszycki D., Shirqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder: clinical and behavioural findings. Archs gen. Psychiat. 48:1991;603-610.
12. Butler P.D., Weiss J.M., Stout J.C., Nemeroff C.B. Corticotropin-releasing factor produces fear-enhancing and behavioural activating effects following infusion into the locus coeruleus. J. Neurosci. 10:1990;176-183.
13. Campeau S., Falls W.A., Cullinan W.E., Helmreich D.L., Davis M., Watson S.J. Elicitation and reduction of fear: behavioural and neuroendocrine indices and brain induction of the immediate-early gene c-fos. Neuroscience. 78:1997;1087-1104.
14. Canteras N.S., Goto M. Fos-like immunoreactivity in the periaqueductal gray of rats exposed to a natural predator. NeuroReport. 10:1999;413-418.
15. Carrive P., Leung P., Harris J., Paxinos G. Conditioned fear to context is associated with increased fos expression in the caudal ventrolateral region of the midbrain periaqueductal gray. Neuroscience. 78:1997;165-177.
16. Chamberlin N.L., Saper C.B. Topographic organization of respiratory responses to glutamate microstimulation of the parabrachial nucleus in the rat. J. Neurosci. 14:1994;6500-6510.
17. Charney D.S., Grillon C., Bremner J.D. The neurobiological basis of anxiety and fear: circuits, mechanisms, and neurochemical interactions (part I). Neuroscientist. 4:1998;35-44.
18. Charney D.S., Heninger G.R., Redmond D.E. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci. 33:1983;19-29.
19. Charney D.S., Woods S.W., Goodman W.K., Heninger G.R. Serotonin function in anxiety. II: Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology. 92:1987;14-24.
20. Coplan J.D., Lydiard R.B. Brain circuits in panic disorder. Biol. Psychiat. 44:1998;1264-1276.
21. Coplan J. D. and Klein D. F. (1996) Pharmacological probes in panic disorder. In Advances in the Neurobiology of Anxiety Disorders (eds Westenberg H. G. M., Den Boer J. A. and Murphy D. L.). John Wiley, New York.
22. Dorow R., Horowski R., Paschelke G., Amin M., Braestrup C. Severe anxiety induced by FG-7142, a β-carboline ligand for benzodiazepine receptors. Lancet. 9:1983;98-99.
23. Duncan G.E., Knapp D.J., Breese G.R. Neuroanatomical characterization of Fos induction in rat behavioural models of anxiety. Brain Res. 713:1996;79-91.
24. Fanselow M.S. Neural organization of the defensive behavior system responsible for fear. Psychom. Bull. Rev. 1:1994;429-438.
25. File S.E., Pellow S. The anxiogenic action of FG-7142 in the social interaction test is reversed by chlordiazepoxide and Ro 15-1788 but not by CGS. Archs int. Pharmacodyn. Ther. 271:1984;198-205.
26. Goddard A.W., Charney D.S. Toward an integrated neurobiology of panic disorder. J. clin. Psychiat. 58:1997;4-11.
27. Graeff F.G. Neuroanatomy and neurotransmitter regulation of defensive behaviors and related emotions in mammals. Brazilian J. med. Res. 27:1994;811-829.
28. Graeff F. G. (1990) Neurotransmitters in the dorsal periaqueductal gray and animal models of panic anxiety. In New Concepts in Anxiety (eds Briley M. and File S. E.). Macmillan, London.
29. Graeff F.G., Silveira R.L., Nogueira R.L., Audi E.A., Oliveira R.M.W. Role of amygdala and periaqueductal gray in anxiety and panic. Behav. Brain Res. 58:1993;123-131.
30. Guimaraes F. S., Russo A. S., de Aguiar J. C., Ballejo G. and Graeff F. G. (1992) Anxiogenic-like effects of CCK-8 microinjected into the dorsal periaqueductal grey of rats in the elevated plus maze. In Multiple Cholecystokinin Receptors in the CNS (eds Cooper S. J., Iversen S. D. and Iversen L. L.). Oxford University Press, Oxford.
31. Harro J., Vasar E., Bradwejn J. CCK in animal and human research on anxiety. Trends pharmac. Sci. 14:1993;244-249.
32. Hinks G.L., Brown P., Field M., Poat J.A., Hughes J. The anxiolytics CI-988 and chlordiazepoxide fail to reduce immediate early gene mRNA stimulation following exposure to the rat elevated X-maze. Eur. J. Pharmac. 312:1996;153-161.
33. Jenck F., Moreau J.L., Martin J.R. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiat. Res. 57:1995;181-191.
34. Jerabek I., Boulenger J.P., Lavallee Y.J., Jolicoeur F.B. Psychological predictors of CCK4-induced panic-like symptoms. Hum. Psychopharmac. 13:1998;35-42.
35. Kennet G.A., Whitton P., Shah K., Curzon G. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur. J. Pharmac. 164:1989;445-454.
36. Lovick T.A. Midbrain and medullary regulation of defensive cardiovascular functions. Prog. Brain Res. 107:1996;301-313.
37. Mongeau R., Marsden C. Effect of central and peripheral administrations of cholecystokinin-tetrapeptide on panic-like reactions induced by stimulation of the dorsal periaqueductal grey area in the rat. Biol. Psychiat. 42:1997;335-344.
38. Moorman J.M., Jackson A., Grahame-Smith D.G., Leslie R.A. Induction of c-fos in rat forebrain by pharmacological manipulation of 5-hydroxytryptamine. Neuroscience. 68:1995;1089-1096.
39. Murphy D.L., Mueller E.A., Hill J.L., Tolliver T.J., Jacobson F.M. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology, Berlin. 98:1989;275-282.
40. Myers M.G. Effects of caffeine on blood pressure. Archs intern. Med. 148:1988;1189-1193.
41. Otter M., Matto V., Soukand R., Skrebuhhova T., Allikmets L., Harro J. Characterization of rat exploratory behaviour using the exploration box test. Meth. Find. exp. clin. Pharmac. 19:1997;683-691.
42. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic, Sydney.
43. Pratt J.A. The neuroanatomical basis of anxiety. Pharmac. Ther. 55:1992;149-181.
44. Price L. H., Goddard A. W., Barr L. C. and Goodman W. K. (1995) Pharmacological challenges in anxiety disorders. In Psychopharmcology: The Fourth Generation of Progress (eds Bloom F. E. and Kupfer D. J.). Raven, New York.
45. Priolo E., Libri V., Lopilato R., David E., Nappi G., Nistico G. Panic-like attack induced by microinfusion into the locus coeruleus of antagonists and inverse agonists at GABAA-receptors in rodents. Funct. Neurol. 6:1991;393-403.
46. Rachman S. (1998) The nature of anxiety. In Anxiety (ed. Brewin C. R.). Psychology Press, Hove.
47. Radulovic J., Kammermeier J., Spiess J. Relationship between fos production and classical fear conditioning: effects of novelty, latent inhibition, and unconditioned stimulus preexposure. J. Neurosci. 18:1998;7452-7461.
48. Redmond D.E. Jr, Huang Y.H., Snyder D.R., Maas J.W. Behavioural effects of stimulation of the nucleus locus coeruleus in the stump-tailed monkey Macaca arctoides. Brain Res. 116:1976;502-510.
49. Russo A.S., Guimaraes F.S., De Aguiar J.C. Role of benzodiazepine receptors located in the dorsal periaqueductal grey in anxiety. Psychopharmacology. 110:1993;198-202.
50. Sandner G., Oberling P., Silveira M.C., Di Scala G., Rocha B., Bagri A., Depoortere R. What brain structures are active druring emotions? Effects of brain stimulation elicited aversion on c-fos immunoreactivity and behaviour. Behav. Brain Res. 58:1993;9-18.
51. Silveira M.C.L., Sandner G., Graeff F.G. Induction of Fos immunoreactivity in the brain by exposure to the elevated plus-maze. Behav. Brain Res. 56:1993;115-118.
52. Singewald N., Zetterstrom T., Sharp T. Common induction of fos expression in specific areas of the fear circuitry by different anxiogenic/panicogenic drugs. Soc. Neurosci. Abstr. 25:1999;163.
53. Teppema L.J., Veening J.G., Kranenburg A., Dahan A., Berkenbosch A., Olivier C. Expression of c-fos in the rat brainstem after exposure to hypoxia and to normoxic and hyperoxic hypercapnia. J. comp. Neurol. 388:1997;169-190.
54. Uhde T.W., Boulenger J.B., Post R.M., Siever L.J., Vittone B.J., Jimerson D.C., Roy-Byrne P.P. Fear and anxiety: relationship to noradrenergic function. Psychopathology. 17:1984;8-23.
55. Van Megen H.J.G.M., Westenberg H.G.M., den Boer J.A., Kahn R.S. Cholecystokinin in anxiety. Eur. Neuropsychopharmac. 6:1996;263-280.
56. Wallis C., Lal H. A discriminative stimulus produced by 1-(3-chlorophenyl)-piperazine (mCPP) as a putative animal model of anxiety. Prog. Neuro-Psychopharmac. biol. Psychiat. 22:1998;547-565.
57. Webb J.K., Rupniak N.M.J., Boyce S. Inhibition of pentagastrin-induced pressor in conscious rats by the CCK-B receptor antagonist CI-988 and chlordiazepoxide. Regul. Pept. 61:1996;71-76.
58. Zacharko R.M., Koszycki D., Mendella P.D., Bradwejn J. Behavioural, neurochemical, anatomical and electrophysiological correlates of panic disorder: multiple transmitter interaction and neuropeptide colocalization. Prog. Neurobiol. 47:1995;371-423.